Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cobicistat/darunavir - Janssen R&D Ireland

Drug Profile

Cobicistat/darunavir - Janssen R&D Ireland

Alternative Names: Darunavir/cobicistat; DRV/COBI; G 006; JNJ-48763364/TMC114; Prezcobix; Rezolsta; TMC114/ JNJ-48763364

Latest Information Update: 20 Oct 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences; Tibotec Pharmaceuticals
  • Developer Gilead Sciences; Janssen R&D Ireland; Janssen Research & Development
  • Class Antiretrovirals; Carbamates; Deoxyribonucleosides; Morpholines; Purines; Pyrimidine nucleosides; Small molecules; Sulfonamides; Thiazoles
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 28 Sep 2022 Janssen completes a phase I bioequivalence study in Healthy volunteers in Belgium (PO) (EudraCT2021-003955-40)
  • 23 Sep 2022 Janssen Research & Development completes a phase I trial in HIV-1 infections (In adolescents, In the elderly, In children, In adults) in South Africa, Spain and USA (PO) (NCT05197075)
  • 19 Aug 2022 Phase-I clinical trials in HIV-1 infections (In adolescents, In adults, In children, In the elderly) in Spain (PO) (NCT05197075)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top